$CBRSBullishMed

Cerebras shares jump as Wall Street initiates coverage with bullish calls

Cerebras Systems (NASDAQ:CBRS) shares rose about 23% after the post–quiet period coverage began for the AI chip designer. At least nine brokerages initiated, with price targets ranging from $250 (Morgan Stanley) to $300 (Mizuho/UBS/Rosenblatt) and $270 (Wedbush). UBS cited fast inference demand, OpenAI pre-payment shipments, and AWS collaborations, setting a $300 target based on 10x EV/Sales of 2029E $11.2B revenue.

7/10
4/10
Med
Bullish
Monday coverage initiation after quiet period expiry; shares up ~23% same day.
Bullish sell-side initiation and high price targets align with AI-chip risk-on sentiment.

Coverage initiation and bullish target-setting are likely to extend near-term momentum, but the thesis hinges on scaling supply for OpenAI and sustaining AWS inference traction.

Cerebras shares jumped ~23% after nine brokerages initiated coverage post-quiet period, with UBS calling it a fast-inference pure play and citing OpenAI pre-payment backlog.

Near-term upside bias vs. peers on continued analyst follow-through; downside risk if supply-chain scaling or hyperscaler ramp disappoints.

Background

Cerebras is a recently debuted AI chip IPO (May 14) using a wafer-scale engine (WSE) architecture aimed at reducing GPU interconnect/memory bottlenecks.

Why it matters

The article frames the stock move as a function of post-quiet-period analyst initiation and a bullish valuation/backlog narrative tied to OpenAI pre-payment and AWS inference collaboration.

Market relevance

Traders get a same-day sentiment catalyst (multiple broker initiations + high targets) and a reiterated execution checklist (supply scaling, hyperscaler ramps, competitive roadmap risk).

Market effects

Reinforces the market narrative that wafer-scale/disaggregated inference architectures could compete with GPU-centric stacks for fast inference workloads.

US-listed AI hardware names may see sentiment spillover as coverage expands post-IPO lockup/quiet period.

Highlights hyperscaler inference competition (OpenAI/AWS) and potential competitive pressure on GPU incumbents’ roadmaps.

Alternative perspectives

Analyst targets may overstate near-term revenue given the article’s own emphasis on needing to scale supply chain nearly tenfold for OpenAI alone.

Nvidia roadmap moves (e.g., Groq integration) and Cerebras’ hybrid business model could limit differentiation if performance/cost advantages don’t translate into sustained hyperscaler deployments.

Key entities

  • Cerebras Systems Inc

    Wafer-scale AI chip designer; shares rose ~23% on analyst coverage initiation and backlog/inference thesis.

  • UBS

    Initiated coverage with Outperform and a $300 target; highlighted OpenAI pre-payment backlog and AWS collaboration.

  • Amazon Web Services

    Cerebras cited as having a growing inference collaboration with AWS.

  • OpenAI

    Cerebras cited as the only current supplier shipping to OpenAI under a pre-payment arrangement.

Related articles

$SNDKMedAI 8/10

These 2 AI Stocks Dominated Headlines in May. How to Play Them in June.

In May, Wall Street rated SanDisk “Strong Buy” overall, with 18 of 22 analysts bullish; one “Moderate Buy” and three “Hold.” The stock has surpassed its mean target, while the Street-high estimate is $3,250 (about 82% upside). Cerebras’ IPO shares rose ~68% on May 14 to $311.07, then fell 24%; market cap is ~$47B. Cerebras reported revenue up 76% YoY to $510M and net income of $237.8M in 2025.

$CRWVLow

3 AI Stocks Born From Recent IPOs That Could Be Bigger Than Their Hype

The article highlights three AI-focused public companies from recent listings: CoreWeave (CRWV), Cerebras (CBRS), and Nebius Group (NBIS). CoreWeave IPO’d March 28, 2025 at $40; it reported Q1 2026 revenue of $2.1B (+112% YoY) and forecasts $12B–$13B for 2026, with $99.4B backlog, but carries $35.1B debt. Cerebras debuted May 14, 2025 at $185; 2025 revenue was $510M (+76% YoY) and it trades at ~100x trailing sales. Nebius Group reported Q1 2026 revenue of $399M (+684% YoY) and guided $3.0B–$3.4B

$CBRSLow

The Cerebras IPO Just Showed Us Exactly What’s Coming With SpaceX

The article argues that AI IPOs may follow a “lockup trap” structure that enables early insider selling. It cites Figma’s IPO: priced at $33, opened at $115, and a performance-based lockup release triggered on Day 1; insiders sold at about $80 within 36 days and the stock later fell to $22. It says Cerebras priced at $185 and opened at $350, and claims SpaceX, Anthropic, and OpenAI may use similar setups.

$NVDALow

Better AI Inference Stock to Own: Nvidia or Cerebras?

The article argues that AI inference may become a larger market than LLM training and compares Nvidia (NVDA) with Cerebras (CBRS). It says Nvidia’s $20 billion “acquisition” of Groq gives it inference-focused LPUs integrated into CUDA and rack systems with GPUs using HBM for prefill and LPUs for decode. It says Cerebras uses wafer-scale SRAM chips sold as CS-3 systems, claiming 15x faster inference but facing yield, cooling, and high valuation concerns.

$CBRSMedAI 9/10

Cerebras Is Down 22% Since Its IPO Popped. Should You Buy It Now?

Cerebras (CBRS) surged 68% on its IPO day but shares have fallen more than 22% since the May 14 close. The company’s wafer-scale AI chips are designed to reduce memory-to-compute bottlenecks, and it says its Kimi K2.6 trillion-parameter model runs 6.7x faster on a ~20-system cluster. OpenAI signed a $20B deal (up to 750 MW through 2028) and Cerebras had $24.6B in remaining performance obligations; it expects ~15% to be recognized in 24 months.